Giuseppe Procopio, Director of the Genitourinary Cancer Unit at National Cancer Institute Foundation, IRCCS, shared a post on X about a recent article by Siamak Daneshmand et al. published in European Urology:
“The THOR2 trial confirms the efficacy of Erdafitinib for patients with FGFR3/2alt-altered HR- or IR- NMIBC.
A promising step forward in personalized bladder cancer care.”
Title: Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study
Authors: Siamak Daneshmand, Renata Zaucha, James W.F. Catto, Ben Tran, Viraj Master, Yair Lotan, Geraldine Pignot, Andrea Tubaro, Nobuaki Shimizu, Nikhil Vasdev, Eugene K. Lee, Giuseppe Procopio, Fernando Galanternik, Lauren Crow, Kris Deprince, Vahid Naini, Spyros Triantos, Mahadi Baig, Wei Zhu, Jodi K. Maranchie
Read the Full Article on European Urology
More posts featuring Bladder Cancer.